Abstract：Objective To explore the mechanism of Qiju Dihuang Pills in the treatment of diabetes mellitus combined with hypertension by network pharmacology. Methods Through traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP), the main active components of Lycii Fructus, Chrysanthemi Flos, Alismatis Rhizoma, Rehmanniae Radix Praeparata, Dioscoreae Rhizoma, Poria, Corni Fructus, Moutan Cortex were searched, and the target prediction was carried out. The related targets of diabetes mellitus and hypertension were searched by GeneCards, TTD and DisGeNET databases. The targets of traditional Chinese medicine were screened by PubChem and Swiss target prediction database. The common targets were selected by intersection of disease and drug targets. The STRING platform was used to construct a protein-protein interaction network model, and the network was topologically analyzed using Cytoscape software to obtain the core target. GO-BP biofunctional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed on the core targets by Metascape software. Results After screening, Qiju Dihuang Pills contained 100 active compounds, 890 targets, 138 targets with diabetes mellitus and hypertension, and 39 core targets. The biological function enrichment function of GO-BP included blood circulation, peptidylserine phosphorylation, transmembrane receptor protein tyrosine kinase signaling pathway, etc. KEGG signaling pathway included VEGF signaling pathway, ErbB signaling pathway, Toll-like receptor cell signaling pathway, and so on. Conclusion This study deeply explores the complex mechanism of Qiju Dihuang Pills in the treatment of diabetes mellitus combined with hypertension with multiple components, multiple targets and multiple pathways, and provides basis and reference for further research on the basic experiments of Qiju Dihuang Pills in the treatment of diabetes mellitus combined with hypertension in the future.
张园 张世超. 基于网络药理学的杞菊地黄丸治疗糖尿病合并高血压的机制研究[J]. 中国医药导报, 2021, 18(11): 4-9.
ZHANG Yuan ZHANG Shichao. Study on the mechanism of Qiju Dihuang Pills in the treatment of diabetes mellitus combined with hypertension based on network pharmacology. 中国医药导报, 2021, 18(11): 4-9.
[1] No authors listed. Hypertension in Diabetes Study（HDS）：Ⅱ. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients [J]. J Hypertens，1993，11（3）：319-325.
[2] 王新梅，魏晓鹏.杞菊地黄丸治疗2型糖尿病合并高血压患者胰岛素抵抗的临床观察[J].现代中医药，2014，34（1）：15-17.
[3] 刘立群.杞菊地黄丸治疗高血压合并糖尿病50例[J].陕西中医，2009，30（11）：1492-1493.
[4] Zhou Y，Zhou B，Pache L，et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets [J]. Nat Commun，2019，10（1）：1523.
[5] 王莎莎，张钊，陈乃宏.枸杞子主要活性成分及药理作用研究进展[J].神经药理学报，2018，8（6）：53.
[6] 周衡朴，任敏霞，管家齐，等.菊花化学成分、药理作用的研究进展及质量标志物预测分析[J].中草药，2019，50（19）：4785-4795.
[7] 朱妍，徐畅.熟地黄活性成分药理作用研究进展[J].亚太传统医药，2011，7（11）：173-175.
[8] 陈梦雨，刘伟，侴桂新，等.山药化学成分与药理活性研究进展[J].中医药学报，2020，48（2）：62-66.
[9] 周迎春，张廉洁，张燕丽.山茱萸化学成分及药理作用研究新进展[J].中医药信息，2020，37（1）：114-120.
[10] 崔鹤蓉，王睿林，郭文博，等.茯苓的化学成分、药理作用及临床应用研究进展[J].西北药学杂志，2019，34（5）：694-700.
[11] 翟春梅，孟祥瑛，付敬菊，等.牡丹皮的现代药学研究进展[J].中医药信息，2020，37（1）：109-114.
[12] 刘珊珊，郭杰，李宗艾，等.泽泻化学成分及药理作用研究进展[J].中国中药杂志，2020，45（7）：1578-1595.
[13] Storkebaum E，Lambrechts D，Carmeliet P. VEGF：once regarded as a specific angiogenic factor，now implicated in neuroprotection [J]. Bioessays，2004，26（9）：943-954.
[14] Moshapa FT，Riches-Suman K，Palmer TM. Therapeutic Targeting of the Proinflammatory IL-6-JAK/STAT Signalling Pathways Responsible for Vascular Restenosis in Type 2 Diabetes Mellitus [J]. Cardiol Res Pract，2019， 2019：9846312.
[15] Gu YJ，Sun WY，Zhang S，et al. Targeted blockade of JAK/STAT3 signaling inhibits proliferation，migration and collagen production as well as inducing the apoptosis of hepatic stellate cells [J]. Int J Mol Med，2016，38（3）：903-911.
[16] 汪伟，李翔，王桃，等.补肾活血中药对大鼠慢性高眼压模型视网膜神经节细胞PI3K/Akt信号转导通路p-Akt表达的影响[J].眼科新进展，2015，35（9）：816-820.
[17] Yang X，Fu Y，Hu F，et al. PIK3R3 regulates PPARα expression to stimulate fatty acid β-oxidation and decrease hepatosteatosis [J]. Exp Mol Med，2018，50（1）：e431.
[18] 黄家喜，鲍翠玉，李晶.PI3K/Akt通路在糖尿病心肌病中的研究进展[J].中国药理学通报，2019，35（9）：1202-1205.
[19] 蒲春华，王沛坚，周鹏.PPARs与盐敏感性高血压及相关靶器官损害[J].成都医学院学报，2014，9（6）：750-753.
[20] Li J，Niu X，Li J，et al. Association of PPARG Gene Polymorphisms Pro12Ala with Type 2 Diabetes Mellitus：A Meta-analysis [J]. Curr Diabetes Rev，2019，15（4）：277-283.
[21] Simons M，Gordon E，Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signaling [J]. Nat Rev Mol Cell Biol，2016，17（10）：611-625.
[22] Sellami N，Lamine LB，Turki A，et al. Association of VEGFA variants with altered VEGF secretion and type 2 diabetes：A case-control study [J]. Cytokine，2018，106：29-34.
[23] 周青霞.血管内皮生长因子及血清胱抑素C对糖尿病合并高血压的诊断价值[J].实用临床医药杂志，2016， 20（9）：168-169.
[24] Benter IF，Sarkhou F，Al-Khaldi AT，et al. The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes [J]. J Drug Target，2015，23（6）：506-518.
[25] 吴欧，刘庆敏，张虎，等.Toll样受体4与高血压合并2型糖尿病发病的相关性[J].医学研究杂志，2013，42（2）：11-13.
京公网安备 11010502046598号